Non-Hodgkin Lymphoma Therapeutics Market Research Report 2020 Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting
The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Table 4: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, IPI Good and Poor Prognostic Factors 18<br />
Table 5: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Ann Arbor Staging System for <strong>Lymphoma</strong> 19<br />
Table 6: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Commonly Used Chemo-Regimens 21<br />
Table 7: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Common Symptoms of <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> 26<br />
Table 8: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Endpoints of Various Chemotherapeutic Regimens (%) 33<br />
Table 9: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Efficacy Comparison of R-CHOP vs. CHOP 34<br />
Table 10: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Efficacy Comparison of CVP vs R-CVP 34<br />
Table 11: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Average Clinical Trial Duration (Months) 43<br />
Table 12: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Deals and Strategic Consolidations, 2006-2014 65<br />
Table 13: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Discovery), 2014 78<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
Table 14: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Preclinical), 2014 79<br />
Table 15: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (IND-filed), 2014 81<br />
Table 16: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Phase I), 2014 82<br />
Table 17: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Phase II), 2014 85<br />
Table 18: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pharmaceutical Pipeline (Phase III), 2014 89<br />
Table 19: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Asia-Pacific, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 90<br />
Table 20: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 90<br />
Table 21: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Australia, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 91<br />
Table 22: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, China, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 91<br />
Table 23: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Japan, <strong>Market</strong> Forecast, 2013-<strong>2020</strong> 9<br />
List of Figures<br />
Figure 1: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Asia-Pacific, Distribution of Prevalence Population, 2013-<br />
<strong>2020</strong> 18
Change language